Abstract

The ability of bacterial pathogens to establish recurrent and persistent infections is frequently associated with their ability to form biofilms. Clostridioides difficile infections have a high rate of recurrence and relapses and it is hypothesized that biofilms are involved in its pathogenicity and persistence. Biofilm formation by C. difficile is still poorly understood. It has been shown that specific molecules such as deoxycholate (DCA) or metronidazole induce biofilm formation, but the mechanisms involved remain elusive. In this study, we describe the role of the C. difficile lipoprotein CD1687 during DCA-induced biofilm formation. We showed that the expression of CD1687, which is part of an operon within the CD1685-CD1689 gene cluster, is controlled by multiple transcription starting sites and some are induced in response to DCA. Only CD1687 is required for biofilm formation and the overexpression of CD1687 is sufficient to induce biofilm formation. Using RNAseq analysis, we showed that CD1687 affects the expression of transporters and metabolic pathways and we identified several potential binding partners by pull-down assay, including transport-associated extracellular proteins. We then demonstrated that CD1687 is surface exposed in C. difficile, and that this localization is required for DCA-induced biofilm formation. Given this localization and the fact that C. difficile forms eDNA-rich biofilms, we confirmed that CD1687 binds DNA in a non-specific manner. We thus hypothesize that CD1687 is a component of the downstream response to DCA leading to biofilm formation by promoting interaction between the cells and the biofilm matrix by binding eDNA.

Details

Title
The cell wall lipoprotein CD1687 acts as a DNA binding protein during deoxycholate-induced biofilm formation in Clostridioides difficile
Author
Auria, Emile 1   VIAFID ORCID Logo  ; Hunault, Lise 2 ; England, Patrick 3 ; Monot, Marc 4   VIAFID ORCID Logo  ; Pipoli Da Fonseca, Juliana 4 ; Matondo, Mariette 5   VIAFID ORCID Logo  ; Duchateau, Magalie 5 ; Tremblay, Yannick D. N. 6 ; Dupuy, Bruno 7 

 Laboratoire Pathogenèse des Bactéries Anaérobies, Institut Pasteur, Université Paris-Cité, UMR-CNRS 6047, Paris, France 
 INSERM UMR1222, Unit of Antibodies in Therapy and Pathology, Institut Pasteur, Université Paris-Cité, Paris, France (GRID:grid.7429.8) (ISNI:0000000121866389); Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Université, INSERM, CNRS, Paris, France (GRID:grid.463810.8) 
 Institut Pasteur, CNRS UMR3528, Plateforme de Biophysique Moléculaire, Paris, France (GRID:grid.428999.7) (ISNI:0000 0001 2353 6535) 
 Institut Pasteur, Plateforme Technologique Biomics, Paris, France (GRID:grid.428999.7) (ISNI:0000 0001 2353 6535) 
 Institut Pasteur, Plateforme Proteomic, Paris, France (GRID:grid.428999.7) (ISNI:0000 0001 2353 6535) 
 University of Saskatchewan, Department of Biochemistry, Microbiology and Immunology, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X) 
 Laboratoire Pathogenèse des Bactéries Anaérobies, Institut Pasteur, Université Paris-Cité, UMR-CNRS 6047, Paris, France (GRID:grid.25152.31) 
Pages
24
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20555008
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2812329339
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.